Trial Profile
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Gilteritinib (Primary) ; Azacitidine; Azacitidine; Cytarabine; Cytarabine; Etoposide; Filgrastim; Fludarabine; Granulocyte colony-stimulating factors; Granulocyte colony-stimulating factors; Idarubicin; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ADMIRAL
- Sponsors Astellas Pharma; Astellas Pharma Global Development
- 17 Aug 2023 Planned End Date changed from 31 Jul 2023 to 31 Jul 2024.
- 19 Jun 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 01 May 2023 Results assessing Patient-reported outcomes, published in the Leukemia and Lymphoma.